Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12452819 | 0.85 | NPSR1 (0.65) | NPSR1CYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL22241983 | 0.84 | NPSR1 (0.70) | ADORA2ANPSR1HCRTR1HCRTR2 | |
| SCHEMBL22241979 | 0.82 | ADORA2A (0.53) | ADORA2ANPSR1HCRTR1HCRTR2 | |
| SCHEMBL12522559 | 0.79 | NPSR1 (0.77) | NPSR1CYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL20667281 | 0.79 | NPSR1 (0.53) | ADORA2ANPSR1CYP1A2CYP2D6MAPT | |
| SCHEMBL20428038 | 0.78 | NPSR1 (0.51) | NPSR1CYP1A2CYP2D6MAPTTSHR | |
| SCHEMBL22242028 | 0.77 | ADORA2A (0.46) | ADORA2ANPSR1HCRTR1HCRTR2 | |
| SCHEMBL24347354 | 0.75 | HCRTR1 (0.39) | HCRTR1HCRTR2MAPTSMN1; SMN2 | |
| SCHEMBL20890465 | 0.73 | HCRTR1 (0.42) | ADORA2AHCRTR1HCRTR2 | |
| SCHEMBL24347523 | 0.73 | HCRTR1 (0.46) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885NPSR1 741/4885HCRTR1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.